Print this page
Radiation
-
NCI 10204 - A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Protocol: 092305Principal Investigator:
-
Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma
Protocol: 102104Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Cervix
Corpus Uteri
Other Female Genital -
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-ZZFX (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma.
Protocol: 102301Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Other Female Genital -
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status.
Protocol: 102302Principal Investigator:
-
Aliza Leiser
Applicable Disease Sites: Other Female Genital -
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors.
Protocol: 102310Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Any Site -
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers.
Protocol: 102402Principal Investigator:
-
Aliza Leiser
Applicable Disease Sites: Ovary -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
-
Archana Sharma
Applicable Disease Sites: Any Site
Ovary
Prostate -
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol.
Protocol: 111706Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Any Site -
A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL).
Protocol: 111707Principal Investigator:
-
Archana Sharma
Applicable Disease Sites: Lymphoid Leukemia -
Phase 1/2 Study to Evaluate Palbociclib (IBRANCE®) in Combination with Irinotecan and Temozolomide or in Combination with Topotecan and Cyclophosphamide in Pediatric Patients with Recurrent or Refractory Solid Tumors.
Protocol: 111901Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Any Site -
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL, Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy.
Protocol: 111911Principal Investigator:
-
Marissa Botwinick
Applicable Disease Sites: Any Site -
A Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma.
Protocol: 111914Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Brain and Nervous System -
A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations.
Protocol: 112102Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Brain and Nervous System -
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor.
Protocol: 112104Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Brain and Nervous System -
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
Protocol: 112106Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Kidney -
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors.
Protocol: 112202Applicable Disease Sites: Any Site